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Background: Implantable cardioverter defibrillators (ICD) reduce the risk of death in patients with left ventricular (LV) dysfunction. We sought to 
determine if race affects outcomes in a cohort of primary prevention ICD patients.
Methods: The PROSE-ICD study is a multi-center prospective study of patients with LV dysfunction and an indication for a primary prevention ICD. 
Patients undergo blood work, ICD device interrogation, and signal-averaged ECG acquisition at implant, at six month intervals, and after an ICD 
shock. Demographic and electrocardiographic differences between African-Americans (AA) and non African-Americans (nAA) were identified and 
utilized to develop multivariate models that predicted total mortality and ICD firings.
Results: Of 923 patients enrolled, 315 (34.1%) were AA. AA were younger (mean 57.8 vs. 63.0 years, p=0.001) and more likely to have diabetes 
(39.4% vs. 28.3%, p=0.003), hypertension (71.1% vs. 54.0%, p<0.001), and higher BMIs (30.3 vs. 29.1, p=0.035). AA had less ischemic 
cardiomyopathy (41.3% vs. 65.5%, p<0.001), lower ejection fractions (21.6% vs. 24.5%, p<0.001), and comparable renal function (GFR 78.6 vs. 
75.1 mL/min, p=0.12). AA had less severe heart failure symptoms (NYHA Class II/III 47.0% / 32.7%) compared to nAA (NYHA Class II/III 39.3% 
/ 37.8%, p=0.035). Among 126 deaths in the population, the adjusted frequency of death in AA was not different from nAA (15.2% vs. 12.8%, 
p=0.063). Compared to nAA, AA died an average of 633.8 vs. 829.5 days (HR 1.79, CI 1.20-2.68, p=0.005), had their first appropriate shock at 
647.8 vs. 435.0 days (HR 0.44, CI 0.21-0.93, p=0.032), and their first shock of any kind at 473.1 vs. 400.3 days from implant (HR 0.57, CI 0.34-
0.97, p=0.037). Only 2.1% AA vs. 15.4% nAA had an appropriate shock prior to death (HR 0.15, CI 0.02-1.36, p=0.092).
Conclusions: AA in this cohort are younger and have similar mortality rates as compared to their nAA counterparts. Despite this, our findings 
suggest that AA die sooner after implant with many of these events occurring prior to receiving their first appropriate ICD shock. Further studies are 
needed to clearly define the reasons underlying this difference so that the benefits of the ICD can be realized.
